Chronic Lymphocytic Leukemia
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | CD20 + | Chronic Lymphocytic Leukemia | Cyclophosphamide, Fludarabine, Rituximab | |
| EMA (1) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Venetoclax | |
| EMA (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Venetoclax | |
| EMA (2) | 17p deletion | Chronic Lymphocytic Leukemia | Venetoclax | |
| EMA (1) | Wild type TP53 | Chronic Lymphocytic Leukemia | Venetoclax | |
| EMA (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| EMA (1) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| EMA (1) | 17p deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| FDA (1) | 17p deletion | Chronic Lymphocytic Leukemia | Ibrutinib |